RiMO Therapeutics Announces Enrollment of the First Patient in Phase 1 Study of RiMO-301 with Radiation in Advanced Tumors
Published on
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.